![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, August 19, 2020 8:25:04 AM
This is a very powerful BRTXQ fundamental valuation that shows through logical deduction how BRTXQ is very likely worth $1.20 per share as a worst case scenario of the Outstanding Shares (OS) being increased to 3,018,986,770 shares.
Within the post I previously made below, I explained how there could be an extra 1,379,783,500 shares added the already Outstanding Shares (OS) of 1,639,203,270 shares which could bring the OS to be 3,018,986,770 shares as a worst case scenario:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157523689
I also explained in that post above how because of one word..."or"... there is a chance that the additional shares will never become part of the OS. For the sake of a worst case scenario of having an OS of roughly 3 billion shares, below was eloquently explained how there is a very good chance that BRTXQ is worth existing in the $1.20 per share area courtesy of Airdale1.
This justifies why Auctus is willing to do the out of the norm logic to be a Joint Partner with BRTXQ to get them through the Chapter 11 Bankruptcy (BK) reorganization to emerge out of BK. You normally would never see an Unsecured Creditor of a company do something like this. Normally they are in line trying to get paid from liquidating the company's assets. Not here. They see something huge to where they believe that it would be better to make sure BRTXQ is funded during the BK and even after they emerge from BK as they are providing them $3,000,000 in funding after providing up to the $15,000,000 DIP Financing to fund BRTXQ after they emerge from bankruptcy to operate for more than a year and to get them back to the NASDAQ as indicated with the earlier posts below:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157581335
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157581329
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157581397
Now the beauty of this post is for all to read how BRTXQ should fundamentally exist to trade in the $1.20 per share area or actually more once the BRTXQ $16.9 Million Tax NOL Carry Forward is incorporated into the valuation of which was left out:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157491233
And for inquiring minds, here's why we know that the common shares are not going to get wiped out as the Equity will be allowed to continue to exist:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157565542
All, please read the BRTXQ valuation post of $1.20 per share below courtesy of Airdale1:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157718376
Knowing when to exit a stock is as key as knowing when to enter. I screwed around with some numbers to see what kind of value BRTXQ will have once BRXT-100 is in use. Several obvious estimates are involved.
What is the value of BRTX's Patented Stem Cell Therapy?
(a) Back pain suffers in the U.S. total 31 million.
Estimated back pain suffers in Europe, 70 million. No direct link information was available on this. (b) Europe has 2.25 times the population of the U.S. (c) (d) They are also on median age 5 years older than the U.S. Population. This means a higher percentage of back problems as age equals health issues. Keeping the percentage equal with the U.S. Population, they would have 70 million suffering from lower back pain issues.
Total back pain sufferers in the U.S. and Europe, 100 million.
(estimate) 100 million back pain sufferers, divided by 40. The 40 represents the years 35-75 when most back problems are manifest, that equals about 2.5 million new back problems annually.
(estimate) Lets say 10% actually do something about their lower back problem. That equals 250,000 surgeries annually. Lets say they converted 25% of the surgeries to BRTX-100, that's 62,500 annually. (What would you rather have, general anesthesia, surgery and therapy, or local anesthetic and two injections with a needle? One would have to assume with a less expensive, less intrusive procedure, a larger percentage of patients would elect BRXT-100 for treatment)
(e) The average cost of a micro-discectomy is about $20,000 including therapy, medication and anesthetics. The average cost of a discectomy is up to $50,000, same costs included. Using the lower number as the cost for comparison.
(estimate) Let's use 50% of the cost of a discectomy or $10,000 per BRTX-100 procedure.
New technologies always have higher profit margins so lets have a 20% net income. $2,000.00 net per surgery.
62,500 annual surgeries x $10,000 = $625,000,000.00 gross annual income
62,500 annual surgeries x $2,000 = $125,000,000.00 net annual income
OS total including the 100 shares per dollar from the reorganization agreement: 3,018,987,105
$125,000,000.00 net income / OS 3,018,987,105 = .0414 per share
(f) Forward Price to earnings of 30.21
TOTAL VALUE .04 * 30 = $1.20 per share
SOURCES:
a) 31 million back pain sufferers in the U.S.:
https://www.statista.com/statistics/188871/adults-in-the-us-with-low-back-pain-by-region/
(b) Europe's Population:
https://worldpopulationreview.com/continents/europe-population
(c) U.S. Median Age:
https://www.worldatlas.com/articles/countries-with-the-highest-median-age.html#:~:text=Europe%20has%20a%20median%20age%20of%2042.7%20years,is%2051.4%20while%20the%20female%20is%2053.7%20years.
(d) Europe's Median Age
https://www.worldatlas.com/articles/countries-with-the-highest-median-age.html#:~:text=Europe%20has%20a%20median%20age%20of%2042.7%20years,is%2051.4%20while%20the%20female%20is%2053.7%20years.
(e) Cost of a Microdiscectomy around $20K
https://www.drkushwaha.com/education/much-back-surgery-cost/ NOTE: 2016 prices
(f) Bio-Technology Forward PE average
http://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/pedata.html NOTE: 2020 PE values
U.S. Population:
https://worldpopulationreview.com/countries/united-states-population
v/r
Sterling
Exit Strategy & Etiquette Thoughts for a Stock
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=128822531
I never give investing advice; only my beliefs for risks in a stock.
Recent BRTX News
- BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 06/27/2024 11:40:00 AM
- BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 06/17/2024 11:05:00 AM
- Shares of Biotech MicroCap Rip on Licensing Talks • AllPennyStocks.com • 06/13/2024 03:40:00 PM
- BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/11/2024 08:28:30 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 06/11/2024 08:23:50 PM
- BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 12:50:00 PM
- BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice • GlobeNewswire Inc. • 05/24/2024 11:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:51:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:45:27 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/16/2024 09:17:17 PM
- BioRestorative Therapies Provides First Quarter 2024 Business Update • GlobeNewswire Inc. • 05/14/2024 08:10:00 PM
- BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity • GlobeNewswire Inc. • 05/08/2024 11:30:00 AM
- BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 • GlobeNewswire Inc. • 04/30/2024 08:15:00 PM
- BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- Biotech Catches Major Premarket Bid Following FDA Clearance • AllPennyStocks.com • 04/16/2024 02:25:00 PM
- BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment • GlobeNewswire Inc. • 04/16/2024 11:45:00 AM
- BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 04/08/2024 11:45:00 AM
- BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants • GlobeNewswire Inc. • 04/03/2024 08:38:00 PM
- BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K • GlobeNewswire Inc. • 04/01/2024 11:45:00 AM
- BioRestorative Therapies to Participate in the 36th Annual ROTH Conference • GlobeNewswire Inc. • 03/11/2024 08:15:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/06/2024 09:34:22 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/15/2024 09:43:54 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/15/2024 09:40:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:27:34 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM